Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Bictegravir/emtricitabine/tenofovir alafenamide treatment: efficacy and tolerability in clinical practice.
  • +9
  • Diana CANETTI,
  • Laura Galli,
  • Riccardo Lolatto,
  • Silvia Nozza,
  • Vincenzo Spagnuolo,
  • Camilla Muccini,
  • Benedetta Trentacapilli,
  • Elena Bruzzesi,
  • Dr. Martina Ranzenigo,
  • Matteo Chiurlo,
  • Antonella Castagna,
  • Nicola Gianotti
Diana CANETTI
IRCCS Ospedale San Raffaele

Corresponding Author:[email protected]

Author Profile
Laura Galli
IRCCS Ospedale San Raffaele
Author Profile
Riccardo Lolatto
IRCCS Ospedale San Raffaele
Author Profile
Silvia Nozza
Universita Vita Salute San Raffaele
Author Profile
Vincenzo Spagnuolo
IRCCS Ospedale San Raffaele
Author Profile
Camilla Muccini
IRCCS Ospedale San Raffaele
Author Profile
Benedetta Trentacapilli
Universita Vita Salute San Raffaele
Author Profile
Elena Bruzzesi
Universita Vita Salute San Raffaele
Author Profile
Dr. Martina Ranzenigo
Universita Vita Salute San Raffaele
Author Profile
Matteo Chiurlo
Universita Vita Salute San Raffaele
Author Profile
Antonella Castagna
IRCCS Ospedale San Raffaele
Author Profile
Nicola Gianotti
IRCCS Ospedale San Raffaele
Author Profile

Abstract

Objectives: Analysis of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) efficacy and safety in virologically-suppressed people living with HIV (PLWH) in clinical practice. Patients and methods: Retrospective cohort study including adult treatment-experienced and virologically suppressed PLWH, switched to BFTAF from June 2019 to June 2021. Efficacy and safety were evaluated as virological failure (VF=2 consecutive HIV-RNA>50 copies/mL or a single HIV-RNA>400 copies/mL) and treatment failure (TF=VF or discontinuation for any reason) until data freezing (August 2022). Results: 1040 PLWH included, 67.8% switched from elvitegravir/cobicistat/FTAF. VF occurred in 4.2% (n=44), with incidence rate of 1.63 per 1000 person-months of follow-up (PMFU) and probability at 24-30 months of 3.8%-4.0%, respectively. Out of the 44 VF, in 75% virological re-supression was achieved while maintaining BFTAF. Discontinuation occurred in 15% after a median time of 13.5 months of follow-up, with incidence rate of 5.67 per 1000 PMFU, and probability at 24-30 months of 11.9%-15.3%, respectively. Main discontinuation reasons were simplification (51.3%) and toxicity (21.8%, involving CNS in half of cases). TF occurred in 18.6% with incidence rate of 7.01 per 1000 PMFU after a median time of 13.6 observation months; probability at 24-30 months was 14.8%-18.4%, respectively. Conclusions: BFTAF proved effective and well tolerated in clinical practice.